Table 2.
TLR signaling modulates myocardial I/R injury and remodeling
| Mice | Infarct Models | Effects in Knockout Mice | References |
|---|---|---|---|
| TLR2−/− | |||
| I/R (30′ I/60 R′) | Smaller infarct sizes, reduced neutrophil recruitment, reduced ROS and cytokines | 35 | |
| Permanent coronary ligation | Improved survival rate, attenuated remodeling, but same infarct sizes at 4 wk | 136 | |
| TLR4 | |||
| C57 BL/10 ScCr C3H/HeJ | I/R (60′ I/24 h R) | Smaller infarct sizes, reduced MPO activity and complement 3 deposition | 118 |
| C3H/HeJ | I/R (60′ I/120′ R) | Smaller infarct sizes, decreased cardiac expression of TNF, MCP-1, and ILs | 28 |
| C3H/HeJ | I/R (60′ I/24 h R) | Smaller infarct sizes, but no gain in LV function | 75 |
| WT with eritoran | I/R (30′ I/120′ R) | Smaller infarct sizes, reduced pJNK, reduced cytokine expression | 134 |
| C3H/HeJ | Permanent coronary ligation | Reduced LV remodeling, improved systolic function, reduced cytokine expression | 149 |
| C57 BL/10 ScCr | Permanent coronary ligation | Improved LV function on day 6 after infarction, improved survival rate, reduced LV remodeling and apoptosis at 4 wk. | 125 |
| MyD88−/− | I/R (30′ I/24 h R) | Smaller infarct sizes, improved LV function, and attenuated cytokine expression and neutrophil recruitment | 36 |
TLR, Toll-like receptor; ROS, reactive oxygen species; MPO, myeloperoxidase; MCP-1, monocyte chemoattractant protein-1; pJNK, phosphorylated JNK; MyD88, myeloid differentiation primary-response gene 88.